Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine in Pediatric Chronic Hepatitis B
NCT02058108Phase 3Terminated
- Sponsor
- Novartis
- Start
- Oct 2014
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 7
01
Overview
A Phase 3 trial of telbivudine in Chronic Hepatitis B (CHB), sponsored by Novartis. Started Oct 2014; status: terminated.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02058108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02058108.